Related Experiment Video
Updated: Jul 7, 2026
A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
Published on: June 15, 2018
Preformulation studies of Clostridium difficile toxoids A and B
Maya S Salnikova1, Sangeeta B Joshi, J Howard Rytting
1Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas 66047, USA.
Abstract:
To enhance the physical stability of Clostridium difficile toxoids A and B, screening for stabilizing compounds was performed. The screening of 30 GRAS compounds at various concentrations and in several combinations was performed in two parts. First, a high-throughput aggregation assay was used to screen for compounds which delayed or prevented aggregation of toxoids under stress conditions (toxoids at pH 5-5.5 were incubated at 55 degrees C for 55 or 75 min). Compounds which stabilized both proteins were further studied for their ability to delay unfolding under conditions leading to a presumably native-like folded state (pH 6.5). The thermal stability of the toxoids on the surface of Alhydrogel was monitored with DSC and also showed significant improvement in the presence of certain excipients. This study has generated information concerning the free and adjuvant bound toxoids behavior under a range of conditions (temperature, solutes) that can be used to design pharmaceutical formulations of enhanced physical stability.
Insights
Researchers screened GRAS compounds to improve the physical stability of Clostridium difficile toxoids A and B. Certain excipients significantly enhanced toxoid stability, aiding pharmaceutical formulation design.
Area of Science:
- Biochemistry
- Pharmaceutical Sciences
- Vaccine Development
Background:
- Clostridium difficile toxoids A and B are crucial vaccine components.
- Enhancing the physical stability of these toxoids is essential for effective pharmaceutical formulations.
- Understanding toxoid behavior under various conditions is key to stability.
Purpose of the Study:
- To screen for compounds that enhance the physical stability of Clostridium difficile toxoids A and B.
- To identify stabilizing excipients for improved vaccine formulation.
- To investigate toxoid behavior under stress conditions.
Main Methods:
- Screening of 30 Generally Recognized As Safe (GRAS) compounds using high-throughput aggregation assays.
- Assessing compound efficacy at various concentrations and combinations.
- Evaluating compound ability to delay unfolding under specific pH and temperature conditions.
- Monitoring thermal stability of toxoids on Alhydrogel using Differential Scanning Calorimetry (DSC).
Main Results:
- Several GRAS compounds demonstrated significant stabilization of Clostridium difficile toxoids A and B.
- Compounds were identified that delay aggregation and unfolding under stress conditions.
- Excipients notably improved the thermal stability of toxoids adsorbed onto Alhydrogel.
Conclusions:
- The study identified effective stabilizers for Clostridium difficile toxoids A and B.
- Findings provide valuable data for designing pharmaceutical formulations with enhanced physical stability.
- This research contributes to the development of more robust and effective vaccines.
